Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post...

[免费ChatGPT] [DeepSeek可用网址] [HTML] mdpi.com

[HTML][HTML] Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada

I Fleury, D MacDonald, M Shafey, A Christofides… - Current …, 2025 - mdpi.com
CAR-T cell therapy has significantly improved outcomes for patients with relapsed or
refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited …
Shrani Navedi Sorodni članki Vse različice: 2 Posnetek

Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma.

C Lewis, A Barraclough, EA Hawkes - Blood, 2025 - Elsevier
Abstract Novel CD3xCD20 bispecific (BsAb) immunotherapies have entered the
armamentarium for follicular lymphoma and diffuse large B-cell lymphoma based on …
Shrani Navedi Sorodni članki Vse različice: 3
[免费ChatGPT] [DeepSeek可用网址] [PDF] haematologica.org

New bispecific antibodies in diffuse large B-cell lymphoma

AG Minson, MJ Dickinson - Haematologica, 2020 - haematologica.org
Abstract The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new
treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma …
Shrani Navedi Sorodni članki Vse različice: 2 V obliki HTML